Nonfatal MI was the largest contributor to this with a 20% reduction in risk (OR 0.80; 95% CI, 0.67-0.96), number-needed-to-treat (NNT) 162. There was no significant reduction in fatal MI, stroke, CVD death, or all-cause mortality....
Number Needed to Treat: 1 in 250 to prevent one first cardiovascular event (primary prevention) Aspirin is still an important mainstay of secondary prevention (known cardiovascular disease) Aspirin is still considered beneficial for primary prevention when 10 year CVD risk >10% in age 40 to 60 ...
such endorsements: the risk reduction of 20% for non-fatal myocardial infarction in the aspirin treatment group corresponding to a number-needed-to-treat (NNT) of 162 did not balance the 31% increased risk of 'non-trivial' bleeding events with a number needed to harm (NNH) equal to 73.Ma...
Nonfatal MI was the largest contributor to this with a 20% reduction in risk (OR 0.80; 95% CI, 0.67-0.96), number-needed-to-treat (NNT) 162. There was no significant reduction in fatal MI, stroke, CVD death, or all-cause mortality. There was no reduction in cancer deaths. ASA ...
The number needed to treat was 4. The median duration of constitutional symptoms (feverishness, shivers) was reduced by four days. Conclusions Although a negative dipstick test for leucocytes and nitrites accurately predicted absence of infection when standard microbiological definitions were used (...
(75-300mg) daily dose of aspirin appeared to cut the total number of cancer cases by 25% after only three years-there were nine cancer cases per 1,000 each year in the aspirin-taking group,compared with 12 per 1,000 for those taking dummy pills.It also reduced the risk of a cancer...
This trial is registered with EudraCT, number 2004-003836-77.Between March 10, 2005, and March 1, 2009, 2557 patients were recruited. 705 patients were assigned to low-dose PPI and no aspirin, 704 to high-dose PPI and no aspirin, 571 to low-dose PPI and aspirin, and 577 to high-...
The number needed to treat was 4. The median duration of constitutional symptoms (feverishness, shivers) was reduced by four days. Conclusions Although a negative dipstick test for leucocytes and nitrites accurately predicted absence of infection when standard microbiological definitions were used (...
A primary outcome event with mRS greater than 1 at day 30 occurred in 221 of 5511 patients (4.0%) randomized to ticagrelor and in 260 of 5478 patients (4.7%) randomized to placebo (HR, 0.83; 95% CI, 0.69-0.99; P = .04), ie, a number needed to treat (NNT) of 133 to ...
The main outcome will be presented as absolute and relative risks (along with 95% confidence intervals) and numbers needed to treat (if applicable). The secondary outcome is poor neonatal outcome. Categorical secondary outcomes will be assessed in the same way as the primary outcome, except that...